← back to search

Matthew W. Fittall

University College Hospital · GB
Area of research
Cancer Research · Oncology
Research interest
Research interests include Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Immune cells in cancer, and Genetic factors in colorectal cancer.
h-index
43
citations
20,407
works
129
NIH funding
primary concept
Medicine
email

Recent publications

Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers
Cell 2025cited by 17position: middledoi
Re: Creta, M., Shariat, S.F., Marra, G. et al. Local salvage therapies in patients with radio-recurrent prostate cancer following external beam radiotherapy: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis (2024)
Prostate Cancer and Prostatic Diseases 2025cited by 0position: contributordoi
Crowd-sourced benchmarking of single-sample tumor subclonal reconstruction
Nature Biotechnology 2024cited by 9position: middledoi
Predicting Survival with Brain Metastases in the Stereotactic Radiosurgery Era: are Existing Prognostic Scores Still Relevant? Or Can we do Better?
Clinical Oncology 2024cited by 5position: contributordoi
Recurrent FOSL1 rearrangements in desmoplastic fibroblastoma.
2023cited by 12position: contributordoi
Author Correction: The evolutionary history of 2,658 cancers
Nature 2023cited by 5position: middledoi
Author Correction: Inferring structural variant cancer cell fraction
Nature Communications 2022cited by 0position: middledoi
Author Correction: Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig
Nature Communications 2022cited by 0position: middledoi
Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes
Cell 2021cited by 550position: middledoi
Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer
Cancer Research 2021cited by 97position: middledoi
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
The Lancet 2020cited by 1,142position: middledoi
The evolutionary history of 2,658 cancers
Nature 2020cited by 1,117position: middledoi
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
The Lancet Oncology 2020cited by 599position: middledoi
Inferring structural variant cancer cell fraction
Nature Communications 2020cited by 56position: middledoi
Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig
Nature Communications 2020cited by 50position: middledoi
Drivers underpinning the malignant transformation of giant cell tumour of bone
The Journal of Pathology 2020cited by 36position: firstdoi
Drivers underpinning the malignant transformation of giant cell tumour of bone.
2020cited by 30position: contributordoi
Drivers underpinning the malignant transformation of giant cell tumour of bone
medRxiv 2020cited by 10position: firstdoi
Characterizing Genetic Intra-Tumor Heterogeneity Across 2,658 Human Cancer Genomes
SSRN Electronic Journal 2020cited by 10position: middledoi
Drivers underpinning the malignant transformation of giant cell tumour of bone
2020cited by 1position: contributordoi
Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways
Cancer Cell 2019cited by 130position: middledoi
Recurrent rearrangements of FOS and FOSB define osteoblastoma
Nature Communications 2018cited by 149position: firstdoi
Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes
bioRxiv (Cold Spring Harbor Laboratory) 2018cited by 108position: middledoi
Anti-Folate Receptor Alpha–Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer
Clinical Cancer Research 2018cited by 92position: middledoi
Portraits of genetic intra-tumour heterogeneity and subclonal selection across cancer types
2018cited by 44position: middle
Abstract 3000: Pervasive intra-tumour heterogeneity and subclonal selection across cancer types
Cancer Research 2018cited by 9position: middledoi
Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling
Cancer Research 2017cited by 79position: middledoi
Targeting folate receptor alpha for cancer treatment
Oncotarget 2016cited by 447position: middledoi
Evaluating biomarkers in melanoma
Frontiers in Oncology 2014cited by 59position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 5 papers (2020–2025)Maxime Tarabichi · Université Libre de Bruxelles5 papers (2018–2020)Stefan M. Pfister · Université du Québec4 papers (2020–2020) · 3 papers (2018–2020)Roberto Tirabosco · European Bioinformatics Institute3 papers (2018–2020)Peter Van Loo · The University of Texas MD Anderson Cancer Center3 papers (2018–2020)Nischalan Pillay · University of Otago3 papers (2018–2020)Jonas Demeulemeester · KU Leuven3 papers (2018–2020)Peter J. Campbell · Quotient Clinical (United Kingdom)3 papers (2018–2020)Fernanda Amary · Royal National Orthopaedic Hospital3 papers (2018–2020)Adrienne M. Flanagan · University College Lahore3 papers (2018–2020)Sam Behjati · Wellcome Sanger Institute3 papers (2018–2020) · 2 papers (2020–2020)Martin Sill · German Cancer Research Center2 papers (2020–2020)Christian Koelsche · Ludwig-Maximilians-Universität München2 papers (2020–2020)David Jones · Mayo Clinic in Florida2 papers (2020–2020)Peter Ellery · The University of Texas MD Anderson Cancer Center2 papers (2020–2020)Adrienne Flanagan · University College London2 papers (2020–2023)Iben Lyskjær · Aarhus University2 papers (2020–2020)Dahmane Oukrif · CRUK Lung Cancer Centre of Excellence2 papers (2020–2020)